Meridian Wealth Partners’s NovoCure NVCR Stock Holding History

Meridian Wealth Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5	Closed	–	–	866
2021 Q1	$0	Buy	+5	New	+$791	﹤0.01%	1410

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meridian Wealth Partners's NVCR Position: Q2 2021 in Review

Meridian Wealth Partners sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 5 shares.

Meridian Wealth Partners first reported a position in NVCR in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

Meridian Wealth Partners reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
Meridian Wealth Partners sold 5 NovoCure shares in Q2 2021.
Meridian Wealth Partners first reported a position in NovoCure in Q1 2021 and held it in 1 quarter.
Meridian Wealth Partners's NovoCure position peaked at $0 in Q1 2021.
361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Meridian Wealth Partners's 13F filing for Q2 2021, filed 12 Aug 2021.